Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387737 | 1.00 | CYP2D6 (0.52) | CYP2D6GRM5CA2SMN1; SMN2EPHX1 | |
| SCHEMBL13642058 | 0.86 | GRM5 (0.47) | CYP2D6GRM5EDNRA | |
| SCHEMBL29219436 | 0.85 | EPHX1 (0.53) | CYP2D6GRM5CA2SMN1; SMN2EPHX1 | |
| SCHEMBL10420999 | 0.84 | GRM5 (0.45) | CYP2D6GRM5SMN1; SMN2GAAMAPT | |
| SCHEMBL3592758 | 0.83 | GRM5 (0.56) | GRM5 | |
| SCHEMBL4533931 | 0.83 | GRM5 (0.44) | CYP2D6GRM5MAPT | |
| SCHEMBL4539463 | 0.83 | GRM5 (0.44) | CYP2D6GRM5MAPT | |
| SCHEMBL4539979 | 0.83 | GRM5 (0.71) | CYP2D6GRM5 | |
| SCHEMBL12068195 | 0.82 | CYP2D6 (0.68) | CYP2D6GRM5SMN1; SMN2TDP1GAA | |
| SCHEMBL15317934 | 0.82 | CYP2D6 (0.68) | CYP2D6GRM5SMN1; SMN2TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
| EP-0674619-A1 | TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| EP-0506434-B1 | Thiazolidinone and oxazolidinone derivatives, their preparation and their use as vasodilators | SANKYO CO (JP) | 1995-02-22 | — | — | EP | disclosed |
| US-5356918-A | Oxazolidinone compounds and method of using the same as a vasodilator | SANKYO COMPANY, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| WO-1994014770-A1 | TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| US-5298516-A | Treatment of cardiovascular disorders, angina | SANKYO COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0506434-A1 | Thiazolidinone and oxazolidinone derivatives, their preparation and their use as vasodilators | Sankyo Company Limited (JP) | 1992-09-30 | — | — | EP | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | ALKBH3, ALKBH1, ALKBH2 | CYP2D6 284/4885GRM5 3964/4885CA2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.